A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Trial Profile

A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Selinexor (Primary) ; Cytarabine; Fludarabine; Hydrocortisone; Methotrexate
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms SELHEM
  • Most Recent Events

    • 01 Mar 2017 Status changed from recruiting to completed.
    • 22 Feb 2017 Planned number of patients changed from 45 to 62.
    • 02 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top